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matrix of likely sample size based on these values ranged from 44 to 193 per group. 
Based on this DPP, a sample of 120 per group was selected as the sample size that 
would deliver clinically meaningful results. ConClusions: A DPP is useful in late 
phase research to define appropriate sample size where no data exist. It is important 
to note that DPP methods do not require significance testing, but the benefit is no 
need for a correction for multiple comparisons at the time of the final analysis.
PRM188
Faulty ConneCtions: Can CRitiCisMs oF netwoRk Meta-analysis in 
niCe subMissions be avoided?
Martin A., Rizzo M., Iheanacho I.
Evidera, London, UK
objeCtives: To assess 1) how network meta-analyses (NMAs) included within 
manufacturer submissions to the National Institute for Health and Care Excellence 
(NICE) have been criticised by its Evidence Review Groups (ERGs); 2) how some 
of these criticisms might be avoided in future submissions; and 3) the extent to 
which such avoidance might increase the likelihood of a new intervention being 
approved. Methods: We reviewed the ERG reports of all NICE technology appraisals 
published since January 2007 to identify those where the manufacturer’s submission 
included an NMA. Subsequently, all criticisms made by the ERG of such analyses 
were analysed to seek common themes; and assess how often any one type of 
criticism was associated with a rejection by NICE. Results: A total of 181 NICE 
technology appraisal reports were evaluated. These covered 243 separate interven-
tions, 83 (34%) of which were drugs for cancer. Overall 37–64% of submissions cited 
NMAs, of which 43–83% were criticised, with this proportion having increased over 
time. Avoidable criticisms related to flaws in the systematic review methodology 
used to identify relevant RCTs for the analysis; inappropriate pooling of data from 
heterogeneous studies; and use of suboptimal statistical approaches in conducting 
the NMA. Unavoidable criticisms related to the lack of RCTs available for competitor 
drugs in the population of interest. However, no association was found between 
flaws in the NMA and a decision by NICE not to approve the use of the intervention. 
Instead, such rejection was associated mainly with a lack of evidence of clinical 
efficacy or cost-effectiveness in the target population. ConClusions: Most criti-
cisms of NMAs could be avoided by a more rigorous and transparent approach to 
conducting and reporting the underlying systematic review and statistical analysis. 
However, rejection of submissions remains a considerable risk where the underly-
ing evidence is weak.
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MethodologiCal Challenges in CoMPaRing toPiCal theRaPies in 
deRMatology in the absenCe oF head to head studies
Greiner R.A.1, Batscheider A.1, Eheberg D.1, Gohlke A.1, Pfiffner C.1, Ehlken B.1,  
Macheleidt O.2, Hutt H.J.2
1IMS Health, Munich, Germany, 2LEO Pharma GmbH, Neu-Isenburg, Germany
objeCtives: German HTA agency requires evidence about the additional benefit of 
a new pharmaceutical versus an appropriate comparator as basis for price negotia-
tions. This is challenging when head-to-head studies (H2HS) or randomized placebo-
controlled trials (RPCTs) are missing and particularly in dermatology, where topical 
therapies in registration trials are usually compared to their individual vehicle. The 
aim of this research was to describe different approaches to assess the additional 
benefit of a new topical therapy under these limitations. Methods: For ingen-
olmebutate-gel (IMG) and the appropriate comparator diclofenac-hyaluronic-acid 
(DHA) bibliographic literature search was conducted for RCTs followed by sequential 
screening on H2HS, comparable endpoints, RPCTs, common bridge comparator, 
H2HS of vehicles alone, RPCTs of vehicles. The similarity of vehicles was assessed 
by comparison of efficacy and safety profile. The lack of H2HS demands to conduct 
the following approaches depending on the comparability of vehicles: 1. An adjusted 
indirect comparison due to Bucher 1997 (vehicles are placebo-like or adequately 
similar) 2. Linkage of direct comparisons due to Wells 2009 (possible when H2HS or 
RPCTs of vehicles are available) 3. Mixed treatment comparison (MTC) (prerequisites 
as mentioned for Bucher). Results: 5 RCTs for IMG versus 3 RCTs for DHA were 
identified with comparable endpoints. No RPCTs for topical therapies or for their 
vehicles, no H2HS of vehicles, no bridge comparator and no clear evidence for the 
adequate similarity of both vehicles could be detected. Therefore, the prerequisites 
of all available statistical methods are not met and cannot thoroughly be applied. 
Notwithstanding these limitations, Bucher (RR[95%KI]: 4.14[2.03;8.47]) and MTC both 
favor IMG significantly while Wells showed non-inferiority (RR[95%KI]: 0.8[2,03;8,47]) 
in the primary endpoint of IMG versus DHA. ConClusions: A definition of ade-
quate similarity for vehicles by German HTA agencies is needed to enable the use of 
methodologically sound indirect comparisons or MTCs in reimbursement dossiers.
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objeCtives: In health technology assessment, decisions about reimbursement 
of new health technologies are largely based on effectiveness estimates. These 
estimates are sometimes also used to predict the health-related quality of life 
outcomes, such as EQ-5D, as part of economic evaluation. However, sometimes 
these effectiveness estimates are not readily available. When many alternative 
instruments measuring these outcomes are being used (and are not all reported) 
or an extended follow-up time of clinical trials is needed to evaluate long-term 
endpoints (and drug development is at an early stage), data on relevant outcomes 
may be limited. The aim of this study was to develop methodology that would allow 
synthesis of all available evidence to assess interventions early and reduce uncer-
tainty around relevant outcomes. Methods: Bayesian multivariate meta-analysis 
both challenges and opportunities for industry. The changes in the DSM-5 criteria 
may translate into changes for how we go about developing medical products to 
treat psychiatric disorders, including ADHD. There will need to be an investment in 
research and education, and sponsors must examine the possibility of developing 
new endpoints and outcome assessments for use in clinical trials.
PRM185
the iMPaCt oF dsM-5 on the develoPMent oF dRugs to tReat MajoR 
dePRessive disoRdeR
Meyers O.I.
Truven Health Analytics, Cleveland, OH, USA
objeCtives: In May 2013, the American Psychiatric Association released the fifth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a 
classification system for psychiatric conditions. DSM-5 brings significant changes 
to many diagnostic categories as compared to the previous edition. The objective 
of this review was to examine the changes in the Major Depressive Disorder (MDD) 
criteria and discuss the impact these changes may have for industry. Methods: 
A line-by-line review of the DSM-5 and DSM-IV criteria for MDD was undertaken. 
Significant changes were highlighted and discussed from the point of view of spon-
sors of clinical trials for psychopharmacologic agents being developed to treat 
MDD. Results: The primary symptom criterion for MDD remains unchanged, 
requiring five of nine symptoms, over a two-week period. The changes of note 
have to do with the differential diagnoses and specifiers. One change that received 
significant attention in the time leading up to the publication of DSM-5 was the 
elimination of the bereavement exclusion, which discounted bereavement after the 
loss a loved one within the first two months as part of the normal grief process. In 
terms of specifiers, a new addition in MDD is “with anxious distress,” referring to 
episodes of depression characterized by at least two of five symptoms of anxiety. 
DSM-5 notes that this is associated with “greater likelihood of treatment nonre-
sponse.” Therefore, this is a factor sponsors may wish to consider in developing their 
trial inclusion/exclusion criteria. ConClusions: The significant changes in DSM-5 
pose both challenges and opportunities for industry. The changes in the DSM-5 
criteria translate into changes for how we go about developing medical products to 
treat psychiatric disorders, including MDD. There will need to be an investment in 
research and education, and sponsors must examine the possibility of developing 
new endpoints and outcome assessments for use in clinical trials.
PRM186
Patient netwoRks as a data souRCe FoR Patient RePoRted outCoMes 
ReseaRCh. CaRenity exPeRienCe
Castejón N.1, Chekroun M.2, Martínez García J.1, Gay C.H.2, Rebollo P.1
1LASER Analytica, Oviedo, Spain, 2carenity.com, Paris, France
objeCtives: To explore the potential of online patient networks (PN) as a viable 
source of PRO data for clinical research. Several PNs have emerged in the last few 
years in different European countries, and as a natural meeting point for chronic 
patients with an active engaged with their communities, they represent a promising 
source of patient reported data. In this original, the experience with the French PN 
“Carenity” is described. Methods: Given the great heterogeneity of the users of 
“Carenity”, and the fact that the test was computer-led by definition, a Computer 
Adaptive Test (CAT) was considered the best choice. The authors decided to use a 
culturally adapted version of CAT-Health system, which measures generic health-
related quality of life (HRQoL). However, in absence of a calibration for the French 
population, a selection of the best items was used, using the Spanish calibration 
as a reference. All patients in the PN were invited to participate in the test. A score 
was estimated for the test using the Spanish parameters, as a rough approxima-
tion of the real score. Age, sex and the main pathology of the subjects were also 
collected. Results: Preliminary results from the first week of data collection show 
601 patients answered (Women: 404, Men: 140). The most frequent reported patholo-
gies and their t-scores were multiple sclerosis (N:92,M:37.91,SD:5.85), fibromyalgia 
(N:81,M:36.65,SD:4.99), ankylosing spondylitis(N:60,M:37.74,SD:5.32) and both types 
of diabetes (I: N:53,M:50.38,SD:10.94, II: N:41,M:48.12,SD:10.04). Significant differ-
ences (p< 0.05) were found in diabetes patients by sex, and between both types 
of diabetes and the other 3 most common pathologies. ConClusions: Carenity 
PN seems to be a fast way to obtain PRO scores directly from patients. Preliminary 
results show differences in the expected direction.
ReseaRCh on Methods – statistical Methods
PRM187
deFining the PRoPeR Methodology to use in a data-Peek FoR PoweR 
(dPP)
Eisenberg D., Wasser T.
HealthCore, Inc., Wilmington, DE, USA
objeCtives: Late phase research is conducted outside the RCT setting where there 
is uncertainty as to how many subjects are needed to find differences between 
groups. Due to the lack of real-world information (non-RCT) in late phase designs, 
there are no tangible inputs for power calculations. This research defines a bias-free 
method to examine data while determining sample size. Methods: As an example 
of the application of a DPP, a study examining the decrease of HGbA1c values in two 
different insulin delivery methods was examined in patients with several comor-
bid conditions. Literature examined found little to no data and a DPP was used to 
determine effect size (ES) and standard deviations (SDs) once 30 patients had been 
enrolled in each group. The DPP procedure was: 1) Determine the test statistic; 2) 
Identify the power formula most appropriate to the test statistic; 3) Determine the 
ES, variation and assumptions needed for the data-peek in the form required by the 
formula; 4) Construct a matrix of possible sample size values; and 5) Select a sample 
size that is obtainable and answers the research question. Results: Data for group 
A demonstrated a mean reduction of 2.75% ±0.760, group B mean reduction of 3.01% 
±0.636. Exact power analysis showed 113 subjects per group would be needed. A 
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objeCtives: To assess the relative efficacy and safety of canagliflozin (CANA), a sodium-
glucose co-transporter (SGLT) inhibitor, as add-on to metformin, compared to sulpho-
nylureas (SU), pioglitazone, DPP-4s, GLP-1s and dapagliflozin. Methods: Bayesian 
network meta-analysis was conducted based on a systematic literature review described 
separately. Outcomes of interest included HbA1c, weight and hypoglycaemia. Networks 
were based on treatment- and dose-specific nodes where possible. Non-informative 
priors were used; selection of fixed versus random-effect model was based on DIC. 
Studies causing inconsistency (identified through the comparison of direct and indirect 
evidence in the network) were identified with a clinical expert and excluded from the 
base case. Results: 25/17/7 studies reported results at 26/52/104 weeks (w) respectively. 
HbA1c-reduction (2) at 26w/52w was best for exenatide 2mg and liraglutide 1.8mg. CANA 
300mg had a higher reduction versus DPP-4s (h= -0.11 to -0.39) and dapagliflozin 10mg 
(= = -0.12 to -0.38) across all time points; while CANA 100mg conferred at least as large 
reductions (= = 0.01 to -0.30 and 0.00 to -0.26 respectively). The analysis at 104w was 
conducted based on the pooling of SUs. CANA 300mg and 100mg ranked first/second 
before liraglutide 1.2mg/1.8mg (s= -0.11/-0.13 and -0.02/-0.04 respectively). Both CANA 
doses had higher weight-reductions than SU, DPP-4s and pioglitazone, and provided 
reductions comparable to GLP-1s and dapagliflozin. Odds ratios for hypoglycaemia ver-
sus SU ranged from 0.03 to 0.11 for DPP-4 and SGLT. ConClusions: NMA of add-on 
therapies to metformin suggests that CANA 300mg is associated with increased HbA1c-
reduction versus DPP-4s and dapagliflozin while CANA 100mg provides at least similar 
effects. Additionally, results suggest increasing relative efficacy of CANA over time versus 
liraglutide and CANA reached at least as large HbA1c reductions as liraglutide at 104w. 
Weight reduction was comparable to GLP-1s and substantially higher than all other 
classes. All classes showed significantly less risk of hypoglycaemia compared to SU.
PRM194
estiMating ChRoniC disease PRevalenCe FRoM ClaiMs data: ReduCing 
bias by aCCounting FoR diseased individuals who do not geneRate 
ClaiMs
Signorovitch J.1, De G.2, Drabo E.3, Guerin A.4
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3University of 
Southern California, Los Angeles, CA, USA, 4Analysis Group, Ltee., Montreal, QC, Canada
objeCtives: Claims data are often used to estimate the prevalence of chronic dis-
eases, typically by dividing the number of patients with disease-related claims 
(e.g., ≥ 1 or ≥ 2 claims) by the number of studied individuals. Such estimates will 
have a downward bias because not all diseased patients will generate disease-
related claims within their enrollment period. This downward bias can be sub-
stantial for underserved diseases that lack effective treatments. We explored 
whether an empirical Bayes estimator for the number of diseased individuals who 
do not generate claims could improve the accuracy of claims-based prevalence 
estimates. Methods: As an example, we studied the prevalence of a rare der-
matological condition without any FDA-approved therapies. After accounting for 
enrollment time, individuals in a large nation-wide claims database were identified 
as having 0, 1, 2, 3, etc., disease-related claims. These counts were modeled using a 
mixture of Poisson distributions, with an unknown mixing distribution. Empirical 
Bayes approaches, which are frequently used to estimate numbers of unobserved 
species in ecological experiments, were used to estimate the number of diseased 
individuals without claims, and to provide adjusted prevalence estimates. Results: 
Out of over 4 million individuals with at least one year of continuous enrollment, 
n= 2,026 had disease-related claims, comprised of n= 1,422 with one claim, n= 317 
with two claims, n= 134 with 3 claims, etc. The traditional method for estimating 
prevalence identified 4.9 cases per 10,000 persons. After applying the empirical 
Bayes approach, the estimated prevalence increased to 7.9 cases per 10,000 persons, 
and became closer to published prevalence estimates based on non-claims data 
sources. ConClusions: In this example application, prevalence estimates based 
on claims data were increased by over 60% by using empirical Bayes approaches to 
account for large numbers of diseased individuals who did not generate claims. The 
increased prevalence estimates were more consistent with the published literature.
PRM195
aPPliCation oF CoPulas in eConoMiC evaluation
Crespo C.1, Monleon A.1, Díaz W.2, Rodriguez C.1, Brosa M.3, Rios M.1
1University of Barcelona, Barcelona, Spain, 2Universidad de Antioquia, Medellin, Colombia, 
3Oblikue Consulting, Barcelona, Spain
objeCtives: To analyse the applicability of copulas distribution in economic evalu-
ation. Methods: We have analyzed data from an observational prospective study 
of patients with allergic rhinitis in Spain (n= 498). Main data were direct cost (€ 2012) 
and Health Related Quality of Life (SF-12). We have calculated the goodness of fit 
for copulas (Gumbel copula, Clayton Copula, Frank Copula, Normal Copula, Plackett 
Copula and T copula) based on the empirical process comparing the empirical cop-
ula with a parametric estimate of the copula derived under the null hypothesis. We 
have used inversion of Kendall’s tau method to fit copulas. A multivariate independ-
ence sample was generated to compare with copulas results. This process was rep-
licated for a 100 times to obtain p-values by bootstrap method. Results: Marginal 
distribution of direct cost was a 3-parameter Gamma distribution (shape= 1.856, 
scale= 0.00324, location= 10.97). Marginal distribution of Health Related Quality of 
Life was associated to a 1- gamma (shape 2.9253 and scale 0.16104). P-value range 
were 0.093 to 0.144 for independent distribution, 0.004 to 0.031 for Gumbel copula, 
0.246 to 0.522 for Clayton Copula, 0.545 to 0.814 for Frank Copula, 0.463 to 0.716 for 
Normal Copula, 0.373 to 0.628 for T Copula and 0.549 to 0.847 for Plackett Copula. 
Frank Copula and Plackett Copula had the best goodness of fit. Kendall’s Tau for 
Fran Copula showed a correlation of -0.4212. ConClusions: Copulas distribution 
allows us to adjust better the non-lineal relation between cost and effectiveness. 
Furthermore, this kind of approach could improve probabilistic sensitivity analyses.
methods have been developed for synthesis of diverse sources of evidence: multiple 
outcomes (including surrogate, potentially short-term endpoints) and other exter-
nal evidence. These methods were applied to an example in rheumatoid arthritis 
where outcomes such as the Health Assessment Questionnaire (HAQ), the Disease 
Activity Score (DAS-28) and the American College of Rheumatology (ACR20) are 
synthesized. External information about correlations between the outcomes was 
included in the form of informative prior distributions. Estimates of HAQ were then 
mapped onto EQ-5D. Also in an alternative approach, the multivariate framework 
was applied to model jointly the utility estimates and the clinical effectiveness out-
comes. Results: The use of multivariate meta-analysis led to reduced uncertainty 
around the effectiveness and utility estimates. Combining the HAQ with DAS-28 
gave a 19% reduction in the uncertainty around the estimate of HAQ and also 16% 
around the estimate of EQ-5D. ConClusions: By allowing all relevant data to be 
incorporated in economic evaluations of new health technologies, this multivariate 
approach to meta-analysis can lead to reduced uncertainty and hence more efficient 
decision-making in health care.
PRM191
netwoRk Meta-analysis oF MultiPle outCoMes: a siMulation study 
and aPPliCation
Achana F., Dequen P., Gray L., Cooper N.J., Abrams K.R., Owen R.K.
University of Leicester, Leicester, UK
The usefulness of a multivariate approach to compare treatments in the context of 
pairwise meta-analysis has been widely demonstrated in the literature. However, 
this approach has not yet been considered for multiple treatment comparisons. 
We believe that extending such methodology to network meta-analysis (NMA) 
will increase the primary evidence base allowing us to compare more interven-
tions across multiple outcomes measures. Borrowing strength between outcome 
measures using multivariate NMA can also potentially increase the precision of 
relative treatment effect estimates and reduce the impact of outcome reporting 
bias.objeCtives: To extend standard NMA to incorporate multiple outcomes of 
interest and evaluate the use of multivariate NMA models through simulated and 
real datasets. Methods: We developed a random effects multivariate NMA model 
to account for the correlation between multiple outcome measures. The potential 
benefits of this method were demonstrated in a simulated example comparing uni-
variate and bivariate NMAs for continuous outcome measures. We further explored 
the application of our multivariate NMA model using a case study comparing anti-
obesity pharmacological interventions for waist circumference, weight change and 
BMI change from baseline. Results: The simulation study showed that through 
use of multivariate NMA the precision in mean relative treatment effects increased 
compared to a standard univariate NMA. This held true under multiple scenarios 
testing model parameters including both within- and between-outcome correla-
tions. Similar findings were obtained from the application to the example data-
set in obesity. ConClusions: Our method proves particularly useful in reducing 
uncertainty around relative effectiveness estimates when the outcomes included 
for analysis are highly correlated. However, the advantages of the multivariate NMA 
are limited where there is little correlation between outcome measures. Further 
work will explore the applicability of multivariate NMA methods to different types 
of outcomes such as binary outcome measures.
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handling vaRiability in tiMe endPoints in Multi-CentRe tiMe and 
Motion (t&M) studies: a Case study oF eRythRoPoiesis-stiMulating 
agents FoR anaeMia ManageMent in 13 CentRes in italy
Kritikou P.1, De Cock E.2, Proskorovsky I.3, Payne K.A.3, Tomic R.4
1Evidera, London, UK, 2Evidera, Barcelona, Spain, 3Evidera, Dorval, QC, Canada, 4Roche S.p.A., 
Monza, Italy
objeCtives: In multi-centre Time and Motion (T&M) studies, time endpoints can 
be highly variable due to differences in centre practices. Our aim was to assess the 
impact of the type of analysis employed on the results of a T&M study. Methods: 
Data from 13 centres were analyzed in relation to each of the following: drug prepa-
ration, distribution, and injection, using three methods. Base case methodology 
included a random intercept generalized linear mixed effect model assuming 
gamma distribution with log link function to account for potential centre cluster-
ing effect and non-normality of the outcome measure. The two alternative methods 
were: standard linear regression (assuming time data are normally distributed) and 
gamma regression with log link function (assuming time data are positively skewed), 
both of which do not account for centre clustering effect. Sample means and vari-
ability as measured by 95% confidence interval (CI)) were also compared. Results: 
For the base case, mean time was 0.53 min (95% CI: 0.33-0.85) for “preparation”, 0.30 
min (95% CI: 0.22-0.40) for “distribution”, and 0.81 min (95% CI: 0.59-1.11) for “injec-
tion”. Mean time resulting from the standard linear regression was markedly higher 
for “preparation”: 0.66 (95% CI: 0.59-0.73), and similar for “distribution” and “injec-
tion”: 0.34 (95% CI: 0.30-0.37) and 0.84 minutes (95% CI: 0.79-0.88), respectively. Using 
the gamma regression yielded similar results to standard linear regression: 0.65 (95% 
CI: 0.59-0.71), 0.31 (95% CI: 0.29-0.34), and 0.83 minutes (95% CI: 0.79-0.88), respec-
tively. The base case scenario detected a “centre-clustering” effect, hence producing 
substantially wider CIs compared to both alternative methods which ignore depend-
ence in the data. ConClusions: Although mean task times remained relatively 
stable across the various methods, 95% CIs were substantially wider for random 
intercept model. If “centre-clustering” is detected, random effects regression models 
must be employed to produce valid confidence intervals around point estimates.
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bayesian netwoRk Meta-analysis to assess Relative eFFiCaCy and 
saFety oF CanagliFlozin in Patients with tyPe 2 diabetes Mellitus 
(t2dM) inadeQuately ContRolled with MetFoRMin
Pacou M.1, Taieb V.1, Abrams K.R.2, Diels J.3, van Sanden S.4, Garg M.5, Schroeder M.6, Kaur V.7, 
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